University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ...

So-called checkpoint proteins on immune cells serve as gatekeepers that are supposed to keep foreign invaders from entering healthy cells. Certain cancers use these checkpoints to avoid detection.

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

Three hours inland from Chennai, India, traffic crawls on a half-finished road past rice fields and cow crossings until it reaches a newer complex of neat white buildings. Among them is the cancer ...

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...